Healthcare Industry News: electrotherapy
News Release - March 31, 2008
Kingfisher Healthcare (KFH) Receives FDA Clearance to Market KFH Energy in the USA And Raises EUR1 Million to Accelerate Market PenetrationLEUVEN, Belgium, March 31 (HSMN NewsFeed) -- Kingfisher Healthcare, a young healthcare company focused on improving patient quality of life, announced today that the U.S. Food and Drug Administration (FDA) has granted the company 510(k) clearance to market KFH Energy in the United States. The patented, high-tech medical device is designed to alleviate fatigue and pain and has received the CE mark in Europe in September 2007.
"We are thrilled to introduce KFH Energy to physicians, specialists, and patients throughout the United States," said Dr. Henk Snyman, CEO of Kingfisher Healthcare, the parent company of Kingfisher Americas. "With the proven success of KFH Energy, we anticipate that this technology will be the first in a suite of natural energy devices for a variety of treatments."
KFH Energy utilizes a unique form of micro current electrotherapy called Bio-Electric Stimulation Therapy (BEST), which is designed to enhance the body's physiological processes. Intended for home use, KFH Energy encapsulates this novel technology in a hand-held device. Its sleek and modern design elements, including the patented touch-screen panel, make the device both convenient and easy to use.
"There is a growing demand among individuals with chronic pain for alternative treatments to improve their condition," said Herb Whitaker, CEO of Kingfisher Americas. "We are excited to have this device available in the States and are committed to improving the lives of those who have been sidelined as a result of symptoms."
For more information about KFH Energy and its availability in the U.S., please visit http://www.kfamericas.com or http://www.kfhealth.com.
About Kingfisher Healthcare
KFH is a healthcare company, developing its own pipeline of proprietary products. It utilizes a technology platform called BEST (Bio-Electric Stimulation Therapy) from which unique products are developed. These products alleviate specific symptoms associated with chronic conditions, including chronic fatigue in post polio syndrome, fibromyalgia, multiple sclerosis and others, and the healing of chronic wounds such as leg ulcers, decubitus ulcers, and others. For more information, see http://www.kfhealth.com.
Source: Kingfisher Healthcare
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.